Real-world evidence supports superior efficacy of prasugrel over ticagrelor in individuals with acute coronary syndrome

2 September 2024 (09:54 - 10:06)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Nils Kruger

Brigham and Women's Hospital, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail

Effect of alirocumab on coronary plaque stratified by atherothrombotic risks

Doctor Y. Ueki (Matsumoto, JP)

Abstract Slides Video

Presentation thumbnail

Lesion-level changes induced by low-density lipoprotein cholesterol lowering therapy in patients with acute myocardial infarction: the pre-specified PACMAN-AMI lesion-level analysis.

Doctor F. Biccire (Bern, CH)

Abstract Slides Video

Presentation thumbnail

Post-PCI anticoagulation with unfractionated heparin in acute coronary syndrome: insight from the STOPDAPT-3 trial

Doctor H. Watanabe (Hirakata, JP)

Abstract Slides Video

Presentation thumbnail

A liberal blood transfusion strategy is safe in patients with myocardial infarction, anemia, and heart failure: lessons from MINT

Doctor A. Goldsweig (Springfield, US)

Abstract Slides Video

Access the full session

Session thumbnail

Tailored approaches to cardiovascular therapy in acute coronary syndromes

The Event

Event poster

ESC Congress 2024

2 September 2024 09:54 CET

You may be interested in

Congress Presentation

Ticagrelor or prasugrel versus clopidogrel in patients with coronary heart disease

Congress Session

Tailored approaches to cardiovascular therapy in acute coronary syndromes

Congress Session

Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources